Thursday, October 28, 2021

Tag: Biotechnology

Emerging Growth Biotechnology Stocks

Biotech Benefits from UpListing – $7.00 Target Price from Think Equity

PetVivo Holdings, Inc. (NASDAQ: PETV), is new to the NASDAQ and has historically been a light trader in terms of volume.  September however marked...

CLS Holdings, (OTCQB: CLSH) New Joint Venture $19 million Sales 61%...

Miami, FL--(September 28, 2021) – EmergingGrowth.com, a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging...

CLS Holdings, (OTCQB: CLSH) FY 2021 $19 Million – 60% Growth...

CLS Holdings achieved multiple records in fiscal 2021, including its highest revenue month, quarter, and fiscal year. Revenue increased by 61.9% year-over-year, with total revenue of $19,292,087 for the fiscal year. This figure also represents a 128.1% increase over revenue in fiscal year 2019.

CLS Holdings, (OTCQB: CLSH) July Sales $1.9 Million 104% increase over...

revenues of $1.9M and a gross margin of 50.4%. These results represent a 40.9% year-over-year increase in monthly revenue, and a 104.1% increase in revenue when compared to July 2019.

Uplisted to NASDAQ Today! Patent Protection and Security in the Healthcare...

Some of the largest healthcare companies in the world include UnitedHealth Group Inc. (NYSE: UNH), Pfizer Inc. (NYSE: PFE), and Abbvie Inc. (NYSE: ABBV). These companies are currently sitting above or close to their all-time-high.

Coming in Hot: CLS Holdings USA, Inc. (OTCQB: CLSH) Branded Division...

City Trees' concentrate category achieved a 153.2% increase in the number of units sold at the retail level in June 2021 compared to June 2020.

Heating Up: CLS Holdings USA (OTCQB: CLSH), Inc. Announces June Results,...

LAS VEGAS, NV / ACCESSWIRE / July 13, 2021 / CLS Holdings USA, Inc. (OTCQB:CLSH) (CSE:CLSH), the ''Company'' or ''CLS'', a diversified cannabis company operating...

CLS Holdings USA, Inc. (OTCQB: CLSH) Achieves Substantial Year-Over-Year Results for...

LAS VEGAS, NV / ACCESSWIRE / June 15, 2021 / CLS Holdings USA, Inc. (OTCQB:CLSH) (CSE:CLSH), the ''Company'' or ''CLS'', a diversified cannabis company operating...

5 Small-Cap Pharma Stocks to Buy in June

While the COVID-19 pandemic has cast doubt on many investments, pharma stocks have never looked better. The need for novel treatments and therapies is...

Celledex gaining traction on experimental Cancer Vaccine while Avalon Globocare paves...

In other ongoing research looking at cancer vaccines, the Cancer Research Institute, in partnership with the Parker Institute for Cancer Immunotherapy, is studying a combination of a vaccine with the adjuvants Flt3 ligand and poly-ICLC plus the checkpoint inhibitor nivolumab (Opdivo) and standard-of-care radiation in castrate-resistant prostate cancer. Results are expected in the next six to 12 months, said Jill O’Donnell-Tormey, chief executive officer and director of scientific affairs at the Cancer Research Institute.